Allakos ALLK

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.00 (+0.87%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Allakos (ALLK)
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $0.26

  • Market Cap

    $23.23 Million

  • Price-Earnings Ratio

    -0.13

  • Total Outstanding Shares

    89.34 Million Shares

  • Total Employees

    131

  • Dividend

    No dividend

  • IPO Date

    July 19, 2018

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    825 industrial road, San carlos, CA, 94070

  • Homepage

    https://www.allakos.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-105.40 Million
Net Cash Flow$-60.07 Million
Net Cash Flow From Investing Activities$45.15 Million
Net Cash Flow From Operating Activities, Continuing$-105.40 Million
Net Cash Flow, Continuing$-60.07 Million
Net Cash Flow From Financing Activities$177,000

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Operating Expenses$186.44 Million
Net Income/Loss$-178.75 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Net Income/Loss Available To Common Stockholders, Basic$-178.75 Million
Basic Average Shares$88.83 Million
Revenues$0

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss Attributable To Parent$-178.34 Million
Other Comprehensive Income/Loss$-178.34 Million
Comprehensive Income/Loss$-178.34 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Non-current Assets$11.55 Million
Fixed Assets$15.73 Million
Other Current Liabilities$12.02 Million
Equity$72.74 Million
Liabilities$51.69 Million
Accounts Payable$3.96 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ALLK from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.